دورية أكاديمية
Inhibition of complement activation by CD55 overexpression in human induced pluripotent stem cell derived kidney organoids.
| العنوان: | Inhibition of complement activation by CD55 overexpression in human induced pluripotent stem cell derived kidney organoids. |
|---|---|
| المؤلفون: | Gaykema LH; Department of Internal Medicine-Nephrology, Leiden University Medical Center, Leiden, Netherlands.; Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden, Netherlands., van Nieuwland RY; Department of Internal Medicine-Nephrology, Leiden University Medical Center, Leiden, Netherlands., Dekkers MC; Department of Internal Medicine-Nephrology, Leiden University Medical Center, Leiden, Netherlands., van Essen MF; Department of Internal Medicine-Nephrology, Leiden University Medical Center, Leiden, Netherlands., Heidt S; Department of Immunology, Leiden University Medical Center, Leiden, Netherlands.; Eurotransplant Reference Laboratory, Leiden University Medical Center, Leiden, Netherlands., Zaldumbide A; Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden, Netherlands., van den Berg CW; Department of Internal Medicine-Nephrology, Leiden University Medical Center, Leiden, Netherlands.; The Novo Nordisk Foundation Center for Stem Cell Medicine (reNEW), Leiden University Medical Center, Leiden, Netherlands., Rabelink TJ; Department of Internal Medicine-Nephrology, Leiden University Medical Center, Leiden, Netherlands.; The Novo Nordisk Foundation Center for Stem Cell Medicine (reNEW), Leiden University Medical Center, Leiden, Netherlands., van Kooten C; Department of Internal Medicine-Nephrology, Leiden University Medical Center, Leiden, Netherlands. |
| المصدر: | Frontiers in immunology [Front Immunol] 2023 Jan 12; Vol. 13, pp. 1058763. Date of Electronic Publication: 2023 Jan 12 (Print Publication: 2022). |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: [Lausanne : Frontiers Research Foundation] |
| مواضيع طبية MeSH: | Induced Pluripotent Stem Cells*, Humans ; Kidney ; CD55 Antigens ; Complement Activation ; Complement System Proteins |
| مستخلص: | End stage renal disease is an increasing problem worldwide driven by aging of the population and increased prevalence of metabolic disorders and cardiovascular disease. Currently, kidney transplantation is the only curative option, but donor organ shortages greatly limit its application. Regenerative medicine has the potential to solve the shortage by using stem cells to grow the desired tissues, like kidney tissue. Immune rejection poses a great threat towards the implementation of stem cell derived tissues and various strategies have been explored to limit the immune response towards these tissues. However, these studies are limited by targeting mainly T cell mediated immune rejection while the rejection process also involves innate and humoral immunity. In this study we investigate whether inhibition of the complement system in human induced pluripotent stem cells (iPSC) could provide protection from such immune injury. To this end we created knock-in iPSC lines of the membrane bound complement inhibitor CD55 to create a transplant-specific protection towards complement activation. CD55 inhibits the central driver of the complement cascade, C3 convertase, and we show that overexpression is able to decrease complement activation on both iPSCs as well as differentiated kidney organoids upon stimulation with anti-HLA antibodies to mimic the mechanism of humoral rejection. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2023 Gaykema, van Nieuwland, Dekkers, van Essen, Heidt, Zaldumbide, van den Berg, Rabelink and van Kooten.) |
| References: | Lancet. 2002 Dec 21-28;360(9350):2039-45. (PMID: 12504401) Stem Cell Reports. 2018 Mar 13;10(3):751-765. (PMID: 29503086) J Am Soc Nephrol. 2008 Dec;19(12):2302-12. (PMID: 18753257) J Immunol. 2004 Sep 15;173(6):3945-52. (PMID: 15356143) Mol Biotechnol. 2018 Aug;60(8):550-562. (PMID: 29916131) N Engl J Med. 2022 May 19;386(20):1889-1898. (PMID: 35584156) Transgenic Res. 2020 Jun;29(3):369-379. (PMID: 32358721) Transplantation. 2008 Apr 27;85(8):1193-9. (PMID: 18431241) Cell. 2007 Nov 30;131(5):861-72. (PMID: 18035408) Am J Transplant. 2022 Apr;22(4):1037-1053. (PMID: 35049121) Nat Biotechnol. 2017 Aug;35(8):765-772. (PMID: 28504668) Blood. 2008 Sep 1;112(5):1759-66. (PMID: 18567839) Nat Commun. 2021 Sep 15;12(1):5456. (PMID: 34526511) Xenotransplantation. 2019 Jan;26(1):e12492. (PMID: 30775816) Cell. 2006 Aug 25;126(4):663-76. (PMID: 16904174) Stem Cell Reports. 2018 Mar 13;10(3):766-779. (PMID: 29429961) J Immunol. 2017 Jun 15;198(12):4837-4845. (PMID: 28500075) Nat Rev Nephrol. 2018 Jan;14(1):26-47. (PMID: 29199277) Nature. 2015 Oct 22;526(7574):564-8. (PMID: 26444236) Gene Ther. 2020 May;27(5):209-225. (PMID: 31900423) J Am Soc Nephrol. 2012 Sep;23(9):1474-85. (PMID: 22797180) J Clin Med. 2020 Jan 17;9(1):. (PMID: 31963521) J Am Soc Nephrol. 2016 Jun;27(6):1778-91. (PMID: 26586691) Nucleic Acids Res. 2016 Jul 27;44(13):6482-92. (PMID: 27280977) Cancer Immunol Immunother. 2006 Aug;55(8):987-95. (PMID: 16485129) Nat Biotechnol. 2019 Mar;37(3):252-258. (PMID: 30778232) Immune Netw. 2018 Feb 20;18(1):e11. (PMID: 29503741) PLoS Med. 2018 May 25;15(5):e1002572. (PMID: 29799874) J Clin Invest. 2000 May;105(10):1363-71. (PMID: 10811844) Proc Natl Acad Sci U S A. 2019 May 21;116(21):10441-10446. (PMID: 31040209) Diabetologia. 2017 Jan;60(1):126-133. (PMID: 27787618) N Engl J Med. 2013 Sep 26;369(13):1215-26. (PMID: 24066742) PLoS One. 2014 Mar 03;9(3):e90387. (PMID: 24594640) Transplantation. 2009 Aug 27;88(4):457-64. (PMID: 19696627) Cell Stem Cell. 2019 Apr 4;24(4):566-578.e7. (PMID: 30853558) Clin J Am Soc Nephrol. 2015 Sep 4;10(9):1636-50. (PMID: 25568220) Stem Cells. 2008 Feb;26(2):496-504. (PMID: 18024421) Xenotransplantation. 2005 Mar;12(2):142-8. (PMID: 15693845) Hum Immunol. 1997 Aug-Sep;56(1-2):106-13. (PMID: 9455499) |
| فهرسة مساهمة: | Keywords: CD55 (DAF); CRISPR-Cas9; complement; iPSCs; immune modulation; kidney organoids; transplantation |
| المشرفين على المادة: | 0 (CD55 Antigens) 9007-36-7 (Complement System Proteins) |
| تواريخ الأحداث: | Date Created: 20230130 Date Completed: 20230131 Latest Revision: 20230202 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC9880527 |
| DOI: | 10.3389/fimmu.2022.1058763 |
| PMID: | 36713440 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1664-3224 |
|---|---|
| DOI: | 10.3389/fimmu.2022.1058763 |